נגישות
menu      
חיפוש מתקדם
תחביר
חפש...
הספר "אוצר וולקני"
אודות
תנאי שימוש
ניהול
קהילה:
אסיף מאגר המחקר החקלאי
פותח על ידי קלירמאש פתרונות בע"מ -
Exploring the molecular approach of COX and LOX in Alzheimer's and Parkinson's disorder
Year:
2020
Source of publication :
Molecular Biology Reports
Authors :
Volume :
Co-Authors:

 Arun Kumar - Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.

 Tapan Behl  - Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.

 Sumit Jamwal - Department of Psychiatry, Yale School of Medicine, Yale University, New Haven, CT, 06511, USA.

Ishnoor Kaur - Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.

Archit Sood - Institute of Plant Sciences, Volcani Center, Agricultural Research Organisation (ARO), Rishon LeTsiyon, Israel.

Puneet Kumar - Department of Pharmacology, School of Basic and Applied Sciences, Central University of Punjab, Bathinda, 151001, India.

Facilitators :
From page:
0
To page:
0
(
Total pages:
1
)
Abstract:

Neuroinflammation is well established biomarker for the major neurodegenerative like Alzheimer's disease (AD) and Parkinson's disease (PD). Cytokines/chemokines excite phospholipase A2 and cyclooxygenases (COX), facilitating the release of arachidonic acid (AA) and docosahexaenoic acid (DHA) from membrane glycerophospholipids, in which the former is oxidized to produce pro-inflammatory eicosanoids (prostaglandins, leukotrienes and thromboxane's), which intensify the neuroinflammatory events in the brain. Similarly, resolvins and neuroprotectins are the metabolized products of docosahexaenoic acid, which exert an inhibitory effect on the production of eicosanoids. Furthermore, an oxidized product of arachidonic acid, lipoxin, is generated via 5-lipoxygenase (5-LOX) pathway, and contributes to the resolution of inflammation, along with anti-inflammatory actions. Moreover, DHA and its lipid mediators inhibit neuroinflammatory responses by blocking NF-κB, inhibiting eicosanoid production, preventing cytokine secretion and regulating leukocyte trafficking. Various epidemiological studies reported, elevated levels of COX-2 enzyme in patients with AD and PD, indicating its role in progression of the disease. Similarly, enhanced levels of 5-LOX and 12/15-LOX in PD models represent their role brain disorders, where the former is expressed in AD patients and the latter exhibits it involvement in PD. The present review elaborates the role of AA, DHA, eicosanoids and docosanoids, along with COX and LOX pathway which provides an opportunity to the researchers to understand the role of these lipid mediators in neurological disorders (AD and PD). The information gathered from the review will aid in facilitating the development of appropriate therapeutic options targeting COX and LOX pathway.

Note:
Related Files :
Alzheimer's disease
arachidonic acid
docosahexaenoic acid
Neuroinflammation
Parkinson’s disease
עוד תגיות
תוכן קשור
More details
DOI :
10.1007/s11033-020-06033-x
Article number:
0
Affiliations:
Database:
PubMed
Publication Type:
מאמר
;
.
Language:
אנגלית
Editors' remarks:
ID:
52064
Last updated date:
02/03/2022 17:27
Creation date:
06/12/2020 20:32
You may also be interested in
Scientific Publication
Exploring the molecular approach of COX and LOX in Alzheimer's and Parkinson's disorder

 Arun Kumar - Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.

 Tapan Behl  - Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.

 Sumit Jamwal - Department of Psychiatry, Yale School of Medicine, Yale University, New Haven, CT, 06511, USA.

Ishnoor Kaur - Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.

Archit Sood - Institute of Plant Sciences, Volcani Center, Agricultural Research Organisation (ARO), Rishon LeTsiyon, Israel.

Puneet Kumar - Department of Pharmacology, School of Basic and Applied Sciences, Central University of Punjab, Bathinda, 151001, India.

Exploring the molecular approach of COX and LOX in Alzheimer's and Parkinson's disorder

Neuroinflammation is well established biomarker for the major neurodegenerative like Alzheimer's disease (AD) and Parkinson's disease (PD). Cytokines/chemokines excite phospholipase A2 and cyclooxygenases (COX), facilitating the release of arachidonic acid (AA) and docosahexaenoic acid (DHA) from membrane glycerophospholipids, in which the former is oxidized to produce pro-inflammatory eicosanoids (prostaglandins, leukotrienes and thromboxane's), which intensify the neuroinflammatory events in the brain. Similarly, resolvins and neuroprotectins are the metabolized products of docosahexaenoic acid, which exert an inhibitory effect on the production of eicosanoids. Furthermore, an oxidized product of arachidonic acid, lipoxin, is generated via 5-lipoxygenase (5-LOX) pathway, and contributes to the resolution of inflammation, along with anti-inflammatory actions. Moreover, DHA and its lipid mediators inhibit neuroinflammatory responses by blocking NF-κB, inhibiting eicosanoid production, preventing cytokine secretion and regulating leukocyte trafficking. Various epidemiological studies reported, elevated levels of COX-2 enzyme in patients with AD and PD, indicating its role in progression of the disease. Similarly, enhanced levels of 5-LOX and 12/15-LOX in PD models represent their role brain disorders, where the former is expressed in AD patients and the latter exhibits it involvement in PD. The present review elaborates the role of AA, DHA, eicosanoids and docosanoids, along with COX and LOX pathway which provides an opportunity to the researchers to understand the role of these lipid mediators in neurological disorders (AD and PD). The information gathered from the review will aid in facilitating the development of appropriate therapeutic options targeting COX and LOX pathway.

Scientific Publication
You may also be interested in